Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Astellas, expanded their antibody-drug conjugate (ADC) collaboration. Under the agreement, Agensys will pay $12 million for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of IND submission. “Combining Agensys’ proprietary antibodies, directed to novel cancer targets, with Seattle Genetics’ industry-leading ADC technology has already led...